TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24670970
Drug: Low-dose control
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose control (LD-C)
Study: 14716700
Drug: Donepezil (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (up to 10 mg once daily)
Study: 12166542
Drug: Rivastigmine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivastigmine (up to 6 mg twice daily)
Study: 10223557
Drug: Cimetidine (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (800 mg twice daily)
Study: 7784338
Drug: pMDI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: pMDI with slow inhalation (27 l/min)
Study: 7784338
Drug: pMDI with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: pMDI with fast inhalation (151 l/min)
Study: 7784338
Drug: Nebuhaler large
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebuhaler large volume spacer device (average inhaled flow 17 l/min)
Study: 6375756
Drug: Bromhexine hydrochloride
Normalized name: bromhexine hydrochloride
DrugBank: Bromhexine (DB09019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine hydrochloride 24 mg per day
Study: 6375756
Drug: Ambroxol 90
Normalized name: AMBROXOL
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol 90 mg per day
Study: 6375756
Drug: Serratiopeptidase 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serratiopeptidase 30 mg per day
Study: 23630210
Drug: 3× HD‐AraC
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3× HD‐AraC (high-dose cytarabine consolidation with three cycles of 18 g/m(2))
Study: 23630210
Drug: MAC/MAMAC/MAC (multiagent
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAC/MAMAC/MAC (multiagent consolidation with two cycles of mitoxantrone 30 mg/m(2) plus cytarabine 12 g/m(2) and one cycle of amsacrine 500 mg/m(2) plus cytarabine 10 g/m(2))
Study: 8770427
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of more than 25 tablets
Study: 8770427
Drug: Loose preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loose preparation of tablets
Study: 8770427
Drug: Blister-pack preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blister-pack preparation of tablets
Study: 1429086
Drug: 20 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 Gy (10 x 2 Gy) to the hemithorax + CYVADIC (cyclophosphamide 500 mg/m2 d 1, vincristine 1 mg/m2 d 1 and 5, adriamycin 40 mg/m2 d 1 and dacarbazine 200 mg/m2 d 1 and 5, several cycles before and after irradiation)
Study: 1429086
Drug: Mitoxantrone (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitoxantrone (14 mg/m2 q 28 d, < or = 6 cycles) followed by 70 Gy (56 x 1.25 Gy, twice a day)
Study: 1429086
Drug: 4‐Epirubicin (110‐130
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4‐Epirubicin (110‐130 mg/m2 q 28 d, < or = 6 cycles) followed by 35 Gy (28 x 1.25 Gy twice a day) to the hemithorax + 36 Gy (9 x 4 Gy every 2 days) to the tumor
Study: 1429086
Drug: Etoposide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (150 mg/m2 1, 3, 5 q 28 d) followed by 38.5 Gy (11 x 3.5 Gy) to the hemithorax
Study: 1429086
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment programs
Study: 3882141
Drug: Cyclosporine (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (12.5 mg/kg/d orally or 3 mg/kg/d i.v.)
Study: 31204776
Drug: CBT-based occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBT-based occupational therapy with sensor monitoring
Study: 25932956
Drug: Galactose (GAL)
Normalized name: Galactose
DrugBank: Galactose (DB11735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galactose (GAL) drink (45 g of CHO, consumed as 300 ml before exercise and 150 ml during exercise)
Study: 25932956
Drug: Glucose (GLU)
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucose (GLU) drink (45 g of CHO, consumed as 300 ml before exercise and 150 ml during exercise)
Study: 25932956
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) drink (artificially sweetened, 45 g of CHO, consumed as 300 ml before exercise and 150 ml during exercise)
Study: 25932956
Drug: Galactose (GAL)
Normalized name: Galactose
DrugBank: Galactose (DB11735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galactose (GAL) drink (45 g of CHO)
Study: 17643057
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 2 x 600 mg orally for 6 weeks
Study: 12394531
Drug: Piracetam (7.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (7.2 g daily for the first 2 weeks during ECT, followed by 4.8 g thereafter)
Study: 10687162
Drug: Diosmectite (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diosmectite (3 g/day for children under 3 years and 6 g/day for children over 3 years)
Study: 10687162
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration solution (ORS) only
Study: 2205129
Drug: Fasting for
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting for 2 hours with 2 mL/kg of water
Study: 25377657
Drug: Daily low-emission
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily low-emission UV treatment and mometasone ointment 0.1%
Study: 25377657
Drug: Mometasone ointment
Normalized name: mometasone Topical Ointment
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone ointment 0.1% alone
Study: 7838889
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg BMS-181168
Study: 7838889
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg BMS-181168
Study: 7838889
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg BMS-181168
Study: 3283620
Drug: Intensive maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive maintenance treatment (rotating combination of HD‐Ara C, mAMSA, 5‐AZA)
Study: 3283620
Drug: Repeated induction
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated induction type chemotherapy (DNM, VCR, Ara C)
Study: 3283620
Drug: Conventional maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional maintenance treatment (from a preceding randomized study)
Study: 30816632
Drug: Implant
Normalized name: IMPLANT (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant
Study: 25650633
Drug: Ultrasound-guided supraclavicular
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided supraclavicular blockade with 30 mL of 0.5% ropivacaine
Study: 25650633
Drug: Ultrasound-guided infraclavicular
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ultrasound-guided infraclavicular blockade with 30 mL of 0.5% ropivacaine
Study: 23974885
Drug: Ocular lubricants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular lubricants (OLs) 4 times a day with Lacri-Lube ointment at night for 3 months
Study: 18775918
Drug: Adjunctive manual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive manual thrombectomy
Study: 16416358
Drug: Amitriptyline-gabapentin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline-gabapentin combination
Study: 10700783
Drug: Rapacuronium 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rapacuronium 2.5 mg kg‐1
Study: 10700783
Drug: Succinylcholine 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine 1.5 mg kg‐1
Study: 25786811
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml ropivacaine 0.5%
Study: 25786811
Drug: 125 ml
Normalized name: 125 ML argatroban 1 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 ml ropivacaine 0.2%
Study: 25786811
Drug: 50 ml
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 ml 0.9% saline (placebo)
Study: 19546825
Drug: Bazedoxifene 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene 10, 20, or 40 mg
Study: 17692722
Drug: Valdecoxib 10
Normalized name: valdecoxib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 10 mg QD
Study: 16678642
Drug: Valdecoxib 20
Normalized name: valdecoxib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 20 mg QD
Study: 16678642
Drug: Valdecoxib 40
Normalized name: valdecoxib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valdecoxib 40 mg QD
Study: 9250559
Drug: Terbinafine 250
Normalized name: terbinafine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 250 mg administered orally once/day for 12 days
Study: 9250559
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered once/day for 12 days
Study: 8318063
Drug: Lovastatin (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (40 mg once daily)
Study: 29720027
Drug: Testosterone enantholactam
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone enantholactam acid ester (250 mg, intramuscular injection every 2 weeks for 6 months)
Study: 29720027
Drug: Placebo (intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intramuscular injection every 2 weeks for 6 months)
Study: 20127900
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion plus N-acetylcysteine (NAC)
Study: 20127900
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (SB) infusion
Study: 3117914
Drug: Ibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (400 mg) pre-operatively
Study: 3117914
Drug: Codeine phosphate
Normalized name: Codeine Phosphate
DrugBank: Codeine (DB00318)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Codeine phosphate (30 mg) pre-operatively
Study: 3117914
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ibuprofen/codeine (400 mg/30 mg) pre-operatively
Study: 3117914
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ibuprofen/codeine (400 mg/30 mg) post-operatively
Study: 3117914
Drug: Diflunisal (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (250 mg) post-operatively
Study: 27300113
Drug: Stretching (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stretching (10 minutes daily before bedtime for 3 weeks)
Study: 18545070
Drug: High-dose simvastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose simvastatin (80 mg/day)
Study: 18545070
Drug: Low-dose simvastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose simvastatin (20 mg/day)
Study: 11760378
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) therapy at a dose of 20 ppm
Study: 9406362
Drug: Teicoplanin administered
Normalized name: teicoplanin
DrugBank: Teicoplanin (DB06149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teicoplanin administered at the time of insertion of central venous catheters
Study: 8123209
Drug: Nimodipine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine (30 and 60 mg, PO)
Study: 8123209
Drug: Verapamil (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (80 mg, PO)
Study: 8123209
Drug: Nimodipine, Verapamil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine, Verapamil, Alcohol (in combination)
Study: 14520164
Drug: Donepezil (DPZ),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (DPZ), 5 to 10 mg for 30 days
Study: 31791389
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy-oriented psychoeducation and self-managed exposure exercises delivered in four manual-based appointments with a general practitioner, along with case management by a trained health care assistant and eHealth support.
Study: 31791389
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy, case management, eHealth support (combined intervention).
Study: 15536018
Drug: Lisinopril therapy
Normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lisinopril therapy for 2 months
Study: 11136273
Drug: Lactobacillus GG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus GG (LGG) ingestion for 5 days before indometacin administration
Study: 11136273
Drug: Heat-killed LGG
Normalized name: heather pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heat-killed LGG ingestion for 5 days before indometacin administration
Study: 11136273
Drug: Indometacin administration
Normalized name: indometacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indometacin administration
Study: 8201379
Drug: ESHAP regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ESHAP regimen (VP‐16 40 mg/m2/d for 4 days, methylprednisolone 500 mg IV daily for 5 days, Ara‐C 2 g/m2 IV on day 5, with cisplatin 25 mg/m2 IV for 4 days)
Study: 3606083
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg rimantadine tablet (single dose) followed by 100 mg twice a day for 10 days (regimen 1)
Study: 3606083
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg rimantadine tablet (single dose) followed by 100 mg once a day for 10 days (regimen 2)
Study: 28332374
Drug: Dexmedetomidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (1 μg/kg) with 0.2% ropivacaine (0.2 mL/kg)
Study: 28332374
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 μg/kg) with 0.2% ropivacaine (0.2 mL/kg)
Study: 26039935
Drug: Lixisenatide 20
Normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 20 μg with sulfonylureas
Study: 26039935
Drug: Lixisenatide 20
Normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lixisenatide 20 μg without sulfonylureas
Study: 20141706
Drug: 30 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/d of lisdexamfetamine dimesylate
Study: 20141706
Drug: 50 mg/d
Normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/d of lisdexamfetamine dimesylate
Study: 20141706
Drug: 70 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 70 mg/d of lisdexamfetamine dimesylate
Study: 17107241
Drug: Haloperidol (5.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (5.4 mg/day)
Study: 16062094
Drug: Risperidone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (4 mg/day)
Study: 17107241
Drug: Olanzapine (15.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olanzapine (15.3 mg/day)
Study: 15116860
Drug: Early invasive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early invasive approach with glycoprotein IIb/IIIa receptor blockers
Study: 9474610
Drug: Topical anesthetic
Normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical anesthetic application
Study: 9474610
Drug: Phentolamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine infusion
Study: 8701596
Drug: Purified influenza
Normalized name: RAYON,PURIFIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified influenza virus (N2) neuraminidase vaccine (NAV)
Study: 8701596
Drug: Conventional trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional trivalent influenza vaccine, Fluogen (Parke‐Davis)
Study: 27373
Drug: Mianserin 3
Normalized name: mianserin 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin 3 X 10 mg daily or 3 X 20 mg daily
Study: 31258920
Drug: Intermittent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent treatment (three times a week) with clarithromycin, rifampicin, and ethambutol for 1 year
Study: 31258920
Drug: Daily treatment
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily treatment with clarithromycin, rifampicin, and ethambutol for 1 year
Study: 26926538
Drug: Tamsulosin (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin (0.01 mg/kg once daily) as adjunctive therapy after shock wave lithotripsy
Study: 24419109
Drug: Not applicable
Normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not applicable (completion of therapy)
Study: 22664978
Drug: Ropivacaine 0.375%
Normalized name: ROPivacaine 0.375%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.375% 10 mL
Study: 22664978
Drug: Ropivacaine 0.375%
Normalized name: ROPivacaine 0.375%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.375% 20 mL
Study: 22664978
Drug: Ropivacaine 0.375%
Normalized name: ROPivacaine 0.375%-NaCl 0.9% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.375% 40 mL
Study: 22664978
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% 5 mL
Study: 19619331
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (budesonide)
Study: 12442238
Drug: Intravenous opiate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous opiate analgesia
Study: 9660383
Drug: Chlorthalidone (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (12.5 to 25 mg/d) with step-up to atenolol (25.0 to 50.0 mg/d) or reserpine (0.05 to 0.10 mg/d)
Study: 27039945
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (rosuvastatin 10 mg/day, candesartan 16 mg/day, hydrochlorothiazide 12.5 mg/day)
Study: 23303315
Drug: Folic acid-iron
Normalized name: folic acid / iron carbonyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic acid-iron (30 mg)
Study: 23303315
Drug: Daily folic
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily folic acid (400 μg)
Study: 12534314
Drug: Controlled-release preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release preparation of VPA
Study: 8729154
Drug: Multiple daily
Normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple daily injections (MDIs)
Study: 1314910
Drug: No radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No radiation therapy (Control)
Study: 20223500
Drug: TNF-alpha inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF-alpha inhibitors
Study: 20223500
Drug: Other biologic
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other biologic agents
Study: 16756149
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids and long acting beta2-agonists
Study: 1797953
Drug: 3 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/day of Andrographis paniculata
Study: 1797953
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day of Andrographis paniculata
Study: 29522174
Drug: Enzalutamide 160
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 160 mg
Study: 23767865
Drug: Salacia extracts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salacia extracts (500 mg/day)
Study: 17765214
Drug: Verbal 'Stories'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal 'Stories' task with concurrent executive function tasks
Study: 16794882
Drug: Individual approach
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual approach in the care of people with dementia; specific details on dosage and duration not available.
Study: 16794882
Drug: Individual everyday
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual everyday situations for residents; specific details on dosage and duration not available.
Study: 16794882
Drug: Communication between
Normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Communication between nurses and residents; specific details on dosage and duration not available.
Study: 16794882
Drug: Personal attention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal attention from nurses; specific details on dosage and duration not available.
Study: 11189683
Drug: Digital rectal
Normalized name: BD Thermometer Digital Rectal (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital rectal examination and blood test for prostate-specific antigen (PSA) for prostate cancer
Study: 9314997
Drug: 50-125 mL
Normalized name: tezacaftor
DrugBank: Tezacaftor (DB11712)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 50-125 mL of 60% nonionic contrast material pushed with 50 mL of saline
Study: 9314997
Drug: 125 mL
Normalized name: 125 ML argatroban 1 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mL of 60% nonionic contrast material administered alone
Study: 28597693
Drug: Modified constraint-induced
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified constraint-induced movement therapy + mental practice
Study: 12415196
Drug: 5‐FU/LEV, weekly,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU/LEV, weekly, 12 months
Study: 10503821
Drug: Omeprazole-metronidazole-clarithromycin treatment
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole-metronidazole-clarithromycin treatment
Study: 8565748
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon therapy